RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

Since your query was left hanging, I'll adress it.
There are no good animal models of SA. In the publication below, there is a nice review of different methods that have been attempted to replicate SA-like intermittent hypoxia (IH) which is the focus of a great deal of research.

Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease.
Dematteis M, Godin-Ribuot D, Arnaud C, Ribuot C, Stanke-Labesque F, Pépin JL, Lévy P.
ILAR J. 2009;50(3):262-81.

There have been a range of compounds thrown at SA in human subjects trials. These studies are reviewed in the publication below. What the review shows is how complicated SA is to study, and goes a long way towards explaining why cor has met with difficulty in getting subjects for its trial.

Pharmacological approaches to the treatment of obstructive sleep apnoea
Malcolm Kohler†, Konrad E Bloch & John R Stradling

My sense is that because ampakines upregulate respiratory networks and hence rescue breathing from opioid-induced depression, cor management decided to take a swing at SA. In my opinion this was ill-considered: a cursory literature search and/or consultation with anybody in the field would have revealed the difficulty of what they were undertaking.

Irrespective of whether it was a good idea or not, their execution has been an abject failure.